UPDATED Jan 28, 2023
Companies with a Future performance score of at least 3, ordered by Future performance score.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
OSLOncoSil Medical | AU$0.042 | 0% | 13.5% | AU$41.8m | n/a | PS39.3x | E57.0% | n/a | ||
CUVClinuvel Pharmaceuticals | AU$27.97 | 5.0% | 22.6% | AU$1.4b | AU$28.94 | PE66.2x | E30.4% | 0.1% | ||
NEUNeuren Pharmaceuticals | AU$7.96 | -9.6% | 144.2% | AU$1.0b | AU$8.03 | PS313.6x | E100.5% | n/a | ||
CU6Clarity Pharmaceuticals | AU$0.84 | -5.1% | 14.3% | AU$218.1m | AU$1.69 | PS33.8x | E82.1% | n/a | ||
TLXTelix Pharmaceuticals | AU$6.92 | -3.1% | 10.9% | AU$2.2b | AU$9.32 | PS76.2x | E89.7% | n/a | ||
PIQProteomics International Laboratories | AU$1.15 | 3.6% | 17.3% | AU$135.9m | AU$1.77 | PS39.6x | E63.6% | n/a | ||
IMMImmutep | AU$0.28 | -5.0% | -21.9% | AU$250.6m | AU$1.17 | PS53.2x | E47.9% | n/a | ||
ARXAroa Biosurgery | AU$1.23 | 3.4% | 50.0% | AU$421.8m | AU$1.51 | PS9x | E88.1% | n/a | ||
MSBMesoblast | AU$0.94 | 2.2% | -13.3% | AU$696.1m | AU$1.48 | PS60.9x | E75.2% | n/a | ||
TRJTrajan Group Holdings | AU$1.95 | 2.4% | -51.5% | AU$295.8m | AU$2.50 | PE173.6x | E43.4% | n/a | ||
PARParadigm Biopharmaceuticals | AU$1.43 | 1.1% | -1.0% | AU$403.6m | AU$2.20 | PS5094.4x | E82.2% | n/a | ||
MDCMedlab Clinical | AU$8.09 | 3.9% | -56.9% | AU$18.5m | AU$18.84 | PS12x | E-10.1% | n/a | ||
CSLCSL | AU$294.70 | -1.4% | 14.4% | AU$142.1b | AU$312.52 | PE44.8x | E15.2% | 1.1% | ||
PBPProbiotec | AU$2.23 | 0% | -1.3% | AU$181.4m | AU$3.27 | PE13.2x | E10.3% | 2.5% | ||
KZAKazia Therapeutics | AU$0.13 | 4.0% | -85.9% | AU$26.6m | n/a | PS2656.4x | E59.8% | n/a | ||
CAUCronos Australia | AU$0.52 | 6.1% | 92.6% | AU$289.4m | n/a | PE48.1x | S35.5% | 1.9% |